Author: admin

Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies | DelveInsight

DelveInsight’s, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook

Key Takeaways from the Systemic Mastocytosis Pipeline Report

  • In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die.
  • In May 2025, Cogent Biosciences Inc. announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
  • DelveInsight’s Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment.
  • The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
  • Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.

Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs

Systemic Mastocytosis Emerging Drugs Profile

  • Avapritinib: Blueprint Medicines

Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM.

  • Masitinib: AB Sciences

Masitinib’s anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study.

The Systemic Mastocytosis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment.
  • Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market

Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight’s detailed report now! @ New Systemic Mastocytosis Drugs

Systemic Mastocytosis Companies

AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.

Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Systemic Mastocytosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight’s expert analysis @ Systemic Mastocytosis Market Drivers and Barriers

Scope of the Systemic Mastocytosis Pipeline Report

  • Coverage- Global
  • Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
  • Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.
  • Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Systemic Mastocytosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Systemic Mastocytosis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Systemic Mastocytosis Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Avapritinib: Blueprint Medicines
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. PA101: Patara Pharma
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. DCC-2618: Deciphera Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Systemic Mastocytosis Key Companies
  20. Systemic Mastocytosis Key Products
  21. Systemic Mastocytosis- Unmet Needs
  22. Systemic Mastocytosis- Market Drivers and Barriers
  23. Systemic Mastocytosis- Future Perspectives and Conclusion
  24. Systemic Mastocytosis Analyst Views
  25. Systemic Mastocytosis Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/systemic-mastocytosis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies | DelveInsight

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight

“Gene Therapy in Ophthalmology Market”
Gene therapy is rapidly emerging as a game-changer in the field of ophthalmology, offering new hope for patients with inherited retinal disorders and other sight-threatening conditions. As conventional treatments often fail to address the underlying genetic causes, gene therapies aim to correct or replace faulty genes, offering long-term or even curative outcomes. DelveInsight’s latest report explores how this cutting-edge approach is reshaping the future of ocular disease treatment.

DelveInsight’s “Gene Therapy in Ophthalmology Market Report” provides a comprehensive overview of the therapeutic landscape, epidemiological trends, and market dynamics for gene therapies in key ophthalmic indications such as Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), Choroideremia, and Age-related Macular Degeneration (AMD). The report covers major markets, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The ophthalmic gene therapy market is expected to witness significant growth through 2034, driven by advancements in vector delivery systems, increasing investment in R&D, and successful regulatory approvals like Luxturna (voretigene neparvovec-rzyl). A growing number of clinical trials, promising pipeline candidates, and supportive regulatory pathways are accelerating innovation across the sector.

With detailed analysis of key players, market drivers, barriers, competitive landscape, and emerging opportunities, this report serves as a vital resource for biopharma companies, investors, clinicians, and researchers seeking to understand the rapidly evolving gene therapy space in ophthalmology.

 

Some of the Key Facts of the Gene Therapy in Ophthalmology Market Report:

• According to DelveInsight, the U.S. led the 7MM Gene Therapy in Ophthalmology market in 2020, valued at around USD 35 million, with continued growth expected through 2034.

• LUXTURNA remains the only approved ophthalmic gene therapy, approved by the FDA in December 2017 and in the EU in November 2018.

• In 2023, the U.S. had an estimated 74,000 eligible Retinitis Pigmentosa cases for gene therapy.

• Estimated diagnosed prevalent cases in the U.S. (2023):

  • Retinitis Pigmentosa: ~113,000

  • Leber Congenital Amaurosis: ~10,000

  • Achromatopsia: ~8,500

  • Wet Age-Related Macular Degeneration (Wet-AMD): ~1.3 million

  • Diabetic Retinopathy: ~5.1 million

• In May 2025, the FDA granted RMAT designation to Opus Genetics’ OPGx-LCA5 for treating Leber congenital amaurosis caused by LCA5 gene mutations. The AAV8-based gene therapy delivers a functional LCA5 gene to the outer retina. The designation was based on early data from an ongoing Phase I/II dose-escalation trial.

• In December 2024, eyeDNA Therapeutics received FDA Rare Pediatric Disease Designation for HORA-PDE6b, its gene therapy targeting inherited retinal dystrophy caused by PDE6b mutations.

• In December 2024, the FDA approved an investigational new drug application for SB-007, a gene therapy using an adeno-associated viral vector to target the genetic cause of Stargardt disease, as announced by SpliceBio.

• Leading companies in the gene therapy in ophthalmology market include Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, GenSight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Bionic Sight, GenSight Biologics, Neuropht Therapeutics, Adverum Biotechnologies, EyeVensys, 4D Molecular Therapeutics, Exegenesis Bio, MeiraGTx, Johnson & Johnson Innovative Medicine, Neuropht Therapeutics, 4D Molecular Therapeutics, Atsena Therapeutics, Ocugen, AbbVie, REGENXBIO, Skyline Therapeutics, Huida Gene Therapeutics, Opus Genetics, and others.

• Emerging acute gene therapy in ophthalmology drugs include BOTARETIGENE SPAROPARVOVEC, AGTC-501, MCO-010, GS030, 4D 125, CTX PDE6B, OCU400, BS01, LUMEVOQ, NR082 (NFS-01), ADVM-022 (AAV.7M8-AFLIBERCEPT), JNJ-1887 (AAVCAGSCD59/JNJ-81201887), EYS 606, 4D 150, EXG102-031, AAV-RPE65, AAV-CNGB3, AAV-CNGA3, NFS-02, 4D 110, ATSN-101, ATSN-201, OCU410, OCU410ST, AGTC-402, AGTC-401, ABBV-RGX-314, SKG0106, HG 004, OPGX-001, and others.

• Gene therapy is rapidly advancing in ophthalmology, driving demand for more effective treatments for inherited and hard-to-treat eye diseases.

 

To know in detail about the gene therapy in ophthalmology market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Gene Therapy in Ophthalmology Market Forecast

 

Gene Therapy in Ophthalmology Overview

Gene therapy is emerging as a transformative approach in ophthalmology, offering the potential to treat or even cure inherited retinal diseases (IRDs) and other ocular disorders at the genetic level. By delivering functional genes to replace or repair mutated ones, gene therapy addresses the root cause of vision loss rather than merely managing symptoms. The eye, with its immune-privileged status, small size, and ease of direct access, makes it an ideal organ for gene therapy interventions. Conditions such as Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), X-linked Retinoschisis (XLRS), and age-related macular degeneration (AMD) are prime targets, with several therapies progressing through clinical trials.

The approval of Luxturna (voretigene neparvovec) by Spark Therapeutics for RPE65-mediated retinal dystrophy marked a milestone, proving the feasibility of gene therapy in ocular indications. Since then, the pipeline has expanded significantly with numerous biotech and pharmaceutical companies investing in adeno-associated virus (AAV) vectors, CRISPR-based editing, and non-viral delivery platforms. As understanding of disease genetics deepens and regulatory pathways become clearer, gene therapy in ophthalmology is poised to reshape the treatment landscape, offering hope for previously untreatable vision disorders.

 

Get a free sample of the gene therapy in ophthalmology market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/gene-therapy-in-ophthalmology-market

 

Gene Therapy in Ophthalmology Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gene Therapy in Ophthalmology Epidemiology Segmentation:

The Gene Therapy in Ophthalmology epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Diagnosed Prevalent Population of Gene therapy in Ophthalmology

• Type-Specific cases of Gene therapy in Ophthalmology

• Gender-Specific cases of Gene therapy in Ophthalmology

• Age-Specific cases of Gene therapy in Ophthalmology

• Site-specific cases of Gene therapy in Ophthalmology

 

Download the report to understand which factors are driving gene therapy in ophthalmology epidemiology trends @ Gene Therapy in Ophthalmology Epidemiology Forecast

 

Gene Therapy in Ophthalmology Drugs Uptake and Pipeline Development Activities

The Gene Therapy in Ophthalmology drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Gene Therapy in Ophthalmology market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the Gene Therapy in Ophthalmology pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

 

Gene Therapy in Ophthalmology Market Outlook

The gene therapy field faced setbacks between 1989 and 2012, but gained momentum after the EU approved the first gene therapy in 2012. This breakthrough spurred growth, with increasing investment and a rising number of early-stage candidates targeting previously untreatable chronic and genetic diseases.

In December 2017, Spark Therapeutics’ LUXTURNA became the first FDA-approved gene therapy for a genetic disease and the first for an inherited retinal disorder, marking a major milestone in ophthalmology. Following its approval, numerous companies entered the space, targeting genes linked to conditions like Retinitis Pigmentosa, LCA, LHON, Achromatopsia, Choroideremia, AMD, Diabetic Retinopathy, and DME.

Among emerging therapies, Beacon’s AGTC-501 is being developed for X-linked Retinitis Pigmentosa, with promising Phase II SKYLINE trial data shared in December 2023. For Diabetic Retinopathy and DME, the pipeline remains limited, with notable candidates including AbbVie/REGENXBIO’s ABBV-RGX-314 and 4D Molecular Therapeutics’ 4D-150.

 

Gene Therapy in Ophthalmology Market Strengths

• The eye is anatomically well-suited for gene therapy due to its small size, immune-privileged environment, and ease of local administration. This minimizes systemic exposure and reduces the risk of immune reactions, making ocular conditions a favorable starting point for gene therapy innovation.

• Following the success of Luxturna, the ophthalmic gene therapy pipeline has rapidly expanded with candidates targeting both rare inherited retinal disorders and more prevalent diseases like AMD. Regulatory agencies are increasingly supportive, providing orphan drug designations and fast-track reviews, which accelerate development timelines.

 

Gene Therapy in Ophthalmology Market Weaknesses

• The cost of gene therapy remains prohibitively high, limiting widespread adoption and reimbursement. Payers and healthcare systems face challenges in evaluating long-term value for single-dose, potentially curative treatments.

• Many therapies are still in early or mid-stage trials, with a lack of long-term real-world evidence on durability, safety, and retreatment potential. This creates uncertainty for clinicians, patients, and investors alike, especially for chronic or progressive conditions.

 

Scope of the Gene Therapy in Ophthalmology Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Gene Therapy in Ophthalmology Companies: Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, GenSight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Bionic Sight, GenSight Biologics, Neuropht Therapeutics, Adverum Biotechnologies, EyeVensys, 4D Molecular Therapeutics, Exegenesis Bio, MeiraGTx, Johnson & Johnson Innovative Medicine, Neuropht Therapeutics, 4D Molecular Therapeutics, Atsena Therapeutics, Ocugen, AbbVie, REGENXBIO, Skyline Therapeutics, Huida Gene Therapeutics, Opus Genetics, and others.

• Key Gene Therapy in Ophthalmology Therapies: BOTARETIGENE SPAROPARVOVEC, AGTC-501, MCO-010, GS030, 4D 125, CTX PDE6B, OCU400, BS01, LUMEVOQ, NR082 (NFS-01), ADVM-022 (AAV.7M8-AFLIBERCEPT), JNJ-1887 (AAVCAGSCD59/JNJ-81201887), EYS 606, 4D 150, EXG102-031, AAV-RPE65, AAV-CNGB3, AAV-CNGA3, NFS-02, 4D 110, ATSN-101, ATSN-201, OCU410, OCU410ST, AGTC-402, AGTC-401, ABBV-RGX-314, SKG0106, HG 004, OPGX-001, and others.

• Gene Therapy in Ophthalmology Therapeutic Assessment: Gene Therapy in Ophthalmology, currently marketed, and Gene Therapy in Ophthalmology emerging therapies

• Gene Therapy in Ophthalmology Market Dynamics: Gene Therapy in Ophthalmology market drivers and Gene Therapy in Ophthalmology market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gene Therapy in Ophthalmology Unmet Needs, KOL’s views, Analyst’s views, Gene Therapy in Ophthalmology Market Access and Reimbursement

 

To learn more about the key players and advancements in the Gene Therapy in Ophthalmology treatment landscape, visit the Gene Therapy in Ophthalmology Market Analysis Report

 

Table of Contents

1. Gene Therapy in Ophthalmology Market Report Introduction

2. Executive Summary for Gene Therapy in Ophthalmology

3. SWOT analysis of Gene Therapy in Ophthalmology

4. Gene Therapy in Ophthalmology Patient Share (%) Overview at a Glance

5. Gene Therapy in Ophthalmology Market Overview at a Glance

6. Gene Therapy in Ophthalmology Disease Background and Overview

7. Gene Therapy in Ophthalmology Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene Therapy in Ophthalmology

9. Gene Therapy in Ophthalmology Current Treatment and Medical Practices

10. Gene Therapy in Ophthalmology Unmet Needs

11. Gene Therapy in Ophthalmology Emerging Therapies

12. Gene Therapy in Ophthalmology Market Outlook

13. Country-Wise Gene Therapy in Ophthalmology Market Analysis (2020–2034)

14. Gene Therapy in Ophthalmology Market Access and Reimbursement of Therapies

15. Gene Therapy in Ophthalmology Market Drivers

16. Gene Therapy in Ophthalmology Market Barriers

17. Gene Therapy in Ophthalmology Appendix

18. Gene Therapy in Ophthalmology Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight

Alcohol Use Disorder Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 30+ Companies and 100+ Therapies | DelveInsight

DelveInsight’s, “Alcohol Use Disorder Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Alcohol Use Disorder pipeline landscape. It covers the Alcohol Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alcohol Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Alcohol Use Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Alcohol Use Disorder Pipeline Outlook

Key Takeaways from the Alcohol Use Disorder Pipeline Report

  • In June 2025, Eli Lilly and Company announced a study to evaluate mazdutide in participants with alcohol use disorder (AUD).
  • In June 2025, Altimmune Inc. announced a phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight.
  • DelveInsight’s Alcohol Use Disorder Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Alcohol Use Disorder treatment.
  • The leading Alcohol Use Disorder Companies such as Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.
  • Promising Alcohol Use Disorder Pipeline Therapies such as Sunobinop, ASP8062, Phytocannabinoid cannabidiol (CBD), Mazdutide, BPL-003, Psilocybin, Ibudilast, GET73 and others.

Stay ahead with the most recent pipeline outlook for Alcohol Use Disorder. Get insights into clinical trials, emerging therapies, and leading companies with Alcohol Use Disorder @ Alcohol Use Disorder Treatment Drugs

Alcohol Use Disorder Emerging Drugs Profile

  • AD04: Adial Pharmaceuticals

AD04, developed by Adial Pharmaceuticals, is a genetically targeted therapeutic agent designed to treat Alcohol Use Disorder (AUD). It works by modulating specific neurotransmitter pathways that are implicated in the brain’s reward and reinforcement circuits related to alcohol consumption. The drug is being developed for patients with particular genetic markers, identified through a proprietary companion diagnostic genetic test, and has shown promise in reducing heavy drinking days in a subgroup of patients during a Phase III clinical trial. AD04’s mechanism of action is believed to involve balancing the activity of the serotonergic and dopaminergic systems, potentially reducing alcohol cravings and consumption.

  • Sunobinop: Imbrium Therapeutics

Sunobinop is an investigational, novel and potential first-in-class oral compound designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions. Currently, the drug is in Phase II stage of its clinical trial for the treatment of alcohol use disorder.

  • BICX104: BiocorRx Pharmaceuticals

BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed to improve patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company’s majority-owned clinical-stage pharmaceutical subsidiary. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Alcohol Use Disorder.

The Alcohol Use Disorder Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Alcohol Use Disorder with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcohol Use Disorder Treatment.
  • Alcohol Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Alcohol Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcohol Use Disorder market

Explore groundbreaking therapies and clinical trials in the Alcohol Use Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Alcohol Use Disorder Drugs

Alcohol Use Disorder Companies

Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.

Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Alcohol Use Disorder Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Alcohol Use Disorder Treatment. Learn about new drugs, Alcohol Use Disorder Pipeline developments, and key companies with DelveInsight’s expert analysis @ Alcohol Use Disorder Market Drivers and Barriers

Scope of the Alcohol Use Disorder Pipeline Report

  • Coverage- Global
  • Alcohol Use Disorder Companies- Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, Imbrium Therapeutics and others.
  • Alcohol Use Disorder Pipeline Therapies- Sunobinop, ASP8062, Phytocannabinoid cannabidiol (CBD), Mazdutide, BPL-003, Psilocybin, Ibudilast, GET73 and others.
  • Alcohol Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Alcohol Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Alcohol Use Disorder Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Alcohol Use Disorder Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alcohol Use Disorder: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alcohol Use Disorder– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. AD04: Adial Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Sunobinop: Imbrium Therapeutics
  12. Early Stage Products (Phase I)
  13. BICX104: BiocorRx Pharmaceuticals
  14. Preclinical and Discovery Stage Products
  15. Drug name: Company name
  16. Inactive Products
  17. Alcohol Use Disorder Key Companies
  18. Alcohol Use Disorder Key Products
  19. Alcohol Use Disorder- Unmet Needs
  20. Alcohol Use Disorder- Market Drivers and Barriers
  21. Alcohol Use Disorder- Future Perspectives and Conclusion
  22. Alcohol Use Disorder Analyst Views
  23. Alcohol Use Disorder Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/alcohol-use-disorder-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alcohol Use Disorder Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 30+ Companies and 100+ Therapies | DelveInsight

Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies | DelveInsight

DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook

Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report

  • In June 2025, M.D. Anderson Cancer Center announced a phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
  • DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
  • The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
  • Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.

Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs

Anaplastic Thyroid Cancer Emerging Drugs Profile

  • Sapanisertib: Takeda

Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models.

  • HLX208: Shanghai Henlius Biotech

BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company’s proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types.

The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
  • Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market

Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Anaplastic Thyroid Cancer Drugs

Anaplastic Thyroid Cancer Companies

Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.

Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight’s expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers

Scope of the Anaplastic Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
  • Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
  • Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Anaplastic Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anaplastic Thyroid Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Sapanisertib: Takeda
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100: AffyImmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Anaplastic Thyroid Cancer Key Companies
  21. Anaplastic Thyroid Cancer Key Products
  22. Anaplastic Thyroid Cancer- Unmet Needs
  23. Anaplastic Thyroid Cancer- Market Drivers and Barriers
  24. Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
  25. Anaplastic Thyroid Cancer Analyst Views
  26. Anaplastic Thyroid Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies | DelveInsight

NK Cell Therapies Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 160+ Therapies | DelveInsight

DelveInsight’s, “NK Cell Therapies Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NK Cell Therapy Pipeline. Dive into DelveInsight’s comprehensive report today! @ NK Cell Therapy Pipeline Outlook

Key Takeaways from the NK Cell Therapy Pipeline Report

  • In June 2025, Artiva Biotherapeutics Inc. announced a Phase 2a study to evaluate the safety and efficacy of AlloNK®, an allogeneic cord blood-derived NK cell therapy, in combination with rituximab in relapsing forms of B-cell dependent rheumatologic diseases.
  • DelveInsight’s NK Cell Therapy Pipeline report depicts a robust space with 140+ active players working to develop 160+ pipeline therapies for NK Cell Therapy treatment.
  • The leading NK Cell Therapy Companies such as Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.
  • Promising NK Cell Therapy Pipeline Therapies such as Tacrolimus, Mycophenolate mofetil, Vax-NK/HCC, Temozolomide, Irinotecan, SLOG Chemotherapy, CellProtect, Isatuximab, and others.

Stay ahead with the most recent pipeline outlook for NK Cell Therapy. Get insights into clinical trials, emerging therapies, and leading companies with NK Cell Therapy @ NK Cell Therapy Treatment Drugs

NK Cell Therapy Emerging Drugs Profile

  • Bemarituzumab: Amgen

Bemarituzumab is a first-in-class, isoform-selective, humanized monoclonal antibody in clinical development as a targeted immunotherapy for tumors that overexpress FGFR2b, a splice variant of a receptor for some members of the fibroblast growth factor (FGF) family. Bemarituzumab blocks FGFs 7, 10, and 22 from binding to FGFR2b, and has been engineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to increase direct tumor cell killing by recruiting natural killer (NK) cells. Clinical results to date suggest that the specificity of bemarituzumab avoids the dose-limiting toxicities that have been noticed with less selective pan-FGFR tyrosine kinase inhibitors that act on multiple FGFRs, including FGFR2. In December 2017, Five Prime and Zai Lab announced a strategic collaboration for the development and commercialization of bemarituzumab in Greater China. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Gastric and Gastroesophageal Junction (GEJ) Cancers.

  • Monalizumab: Innate Pharma

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E, which cancer cells frequently overexpress to protect themselves from NKG2A+ immune cells. By blocking this inhibition, monalizumab prevents HLA-E-expressing tumor cells from evading immune detection. This re-establishes a broad anti-tumor response mediated by NK and T cells, simultaneously enhancing the cytotoxic potential of other therapeutic antibodies. Through its dual action on innate and adaptive immunity, monalizumab holds promise for reactivating immune responses against a variety of solid tumors and hematological malignancies. Currently, the drug is in Phase III for Unresectable Stage III Non-small Cell Lung Cancer and in Phase II for Neoadjuvant NSCLC, other cancer types.

  • L1 t-haNK: ImmunityBio

PD-L1.t-haNK cells are a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins arise from NantKwest’s proprietary NK-92 (aNK) master cell bank. In addition to targeting PD-L1, PD-L1.t-haNK is engineered to produce intracellular IL-2 for enhanced CD16-targeted antibody-dependent cellular cytotoxicity capabilities. Currently, the drug is in the Phase II clinical studies for the treatment of gastric cancer, pancreatic cancer, squamous cell cancer, glioblastoma, and non-small cell lung cancer.

  • M ceNK: ImmunityBio

The first-in-class, memory cytokine-enriched Natural Killer (m-ceNK) cells are the patient’s own NK cells that have been enriched with cytokines, including ImmunityBio’s IL-15 super agonist Anktiva (N-803). These m-ceNK cells, or memory-cytokine enriched NK cells, have been designed for autologous cell therapy, but have also been generated as an allogeneic product from cord blood. M-ceNK provides a unique opportunity in clinics due to its ease of use and potential suitability for use in the ambulatory setting. ImmunityBio has successfully enriched and expanded donor natural killer cells obtained from peripheral blood of donors using a technique called apheresis, to generate a unique NK cell phenotype which exhibits both high cytotoxicity and interferon-g production together with a memory–like effect. M-ceNK cells are currently being investigated in Phase I stage of development for the treatment of Solid Tumor. The company is currently investigating the M-cenk in Phase II stage of development for the treatment of Acute Myeloid Leukemia (AML) and Ovarian cancer, however the details are yet to be announced by the company.

  • DF6002: Dragonfly Therapeutics

DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses. DF6002, Dragonfly’s extended half-life IL12 cytokine, is an investigational immunotherapy being evaluated in adult patients for the treatment of advanced solid tumors. DF6002 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. The drug is currently being investigated in the Phase I/II stage of development for the treatment of solid tumors.

  • oNKord: Glycostem Therapeutics

Allogeneic Natural Killer Cell Therapy (also known as oNKord) comprises natural killer cells (NK-cells) generated ex vivo from umbilical cord blood progenitor cells. The system for the generation of these cells is quite efficient and effective. The process is capable of generating a superior expansion of NK cells, i.e., 5–10,000 fold expansion is achievable. The cells that are produced are of superior quality which is over 95% pure and devoid of contaminating T- and B-cells. These NK cells are already activated and are ready to attack cancer cells. The output of these cells has been proven to be highly reliable and reproducible. As per Glycostem, oNKord are also capable of treating other diseases such as Multiple Myeloma, hematological cancers and solid tumors such as colorectal cancer, head-neck cancer, lung cancer and breast cancer. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML).

  • KUR-501: Athenex

KUR-501 is an autologous cell therapy that is developed by using Cell Medica natural killer T (NKT) cell platform technology in combination with genetically engineered chimeric antigen receptors (CARs) and secretion of the IL-15 cytokine to sustain the activity of the therapeutic cells within the immunosuppressive tumor microenvironment. CAR.GD2-IL-15 NKTs is a GD2 specific chimeric antigen receptor (CAR) and Interleukin-15 Expressing autologous natural killer T-cells. The molecule designed specifically to contain artificial genes called chimeric antigen receptor (CAR), from an antibody called 14g2a that recognizes GD2, a molecule found on almost all neuroblastoma cells (GD2-CAR). The chimeric antigen receptor also contains a gene segment called CD 28 to make the NKT cells last longer. The molecule was further modified by adding a gene expressing Interleukin -15 (IL-15). The combination of these three components showed the most antitumor activity by CAR-expressing NKT cells and improved the cell survival in various animal models. The company currently conducting a Phase I trial in sponsorship with Baylor College of Medicine (BCM) in pediatric patients for the treatment of neuroblastoma.

The NK Cell Therapy Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of NK Cell Therapy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NK Cell Therapy Treatment.
  • NK Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NK Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NK Cell Therapy market

Explore groundbreaking therapies and clinical trials in the NK Cell Therapy Pipeline. Access DelveInsight’s detailed report now! @ New NK Cell Therapy Drugs

NK Cell Therapy Companies

Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

NK Cell Therapy Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule

Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, NK Cell Therapy Pipeline developments, and key companies with DelveInsight’s expert analysis @ NK Cell Therapy Market Drivers and Barriers

Scope of the NK Cell Therapy Pipeline Report

  • Coverage- Global
  • NK Cell Therapy Companies- Amgen, Innate Pharma, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Takeda, Wugen, Affimed Therapeutics, VERAXA, Asclepius Technology Company Group, NKGen Biotech, Sanofi, Indapta Therapeutics, Celularity, GT Biopharma, Biohaven Pharmaceuticals, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics and others.
  • NK Cell Therapy Pipeline Therapies- Tacrolimus, Mycophenolate mofetil, Vax-NK/HCC, Temozolomide, Irinotecan, SLOG Chemotherapy, CellProtect, Isatuximab, and others.
  • NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NK Cell Therapy Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NK Cell Therapy Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Natural Killer (NK) cell therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Bemarituzumab: Amgen
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. L1 t-haNK: ImmunityBio
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. KUR-501: Athenex
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Inactive Products
  18. Natural Killer (NK) cell therapy Key Companies
  19. Natural Killer (NK) cell therapy Key Products
  20. Natural Killer (NK) cell therapy- Unmet Needs
  21. Natural Killer (NK) cell therapy- Market Drivers and Barriers
  22. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
  23. Natural Killer (NK) cell therapy Analyst Views
  24. Natural Killer (NK) cell therapy Key Companies
  25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NK Cell Therapies Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 160+ Therapies | DelveInsight

StarkScapes, LLC Expands Seasonal Service Capabilities for Residential and Commercial Properties in Canton, Ohio

StarkScapes, LLC Expands Seasonal Service Capabilities for Residential and Commercial Properties in Canton, Ohio
StarkScapes, LLC has announced expanded capabilities for seasonal exterior maintenance services across the Canton region, addressing the growing demand for dependable and professional outdoor property care. With the area’s unpredictable climate placing greater pressure on homeowners and businesses, the local company is broadening its team and fleet to provide year-round landscape management.

As part of its expansion, StarkScapes, LLC is streamlining its response times and increasing its availability for both recurring and emergency service requests. The investment includes upgraded equipment, enhanced scheduling technology, and increased staffing during peak seasons. According to company representatives, these changes aim to support long-term customer satisfaction and maintain the visual appeal of Canton’s residential neighborhoods and commercial districts.

This development comes as more property owners seek reliable lawn mowing Canton services that go beyond simple grass cutting. StarkScapes, LLC incorporates trimming, edging, and seasonal fertilization options into customized lawn care plans to ensure consistent curb appeal throughout the growing season.

In addition to summer maintenance, StarkScapes, LLC continues to see rising interest in full-service landscaping in Canton solutions. Services such as mulching, tree and shrub installation, and hardscape design have been instrumental in helping clients enhance property value and outdoor usability. The company also supports sustainable practices, including the selection of water-efficient plants and environmentally friendly ground cover options.

With Northeast Ohio prone to heavy winter storms, the company has also strengthened its capacity for snow removal in Canton services. New equipment and expanded crews are set to improve access for residential driveways, commercial lots, and municipal pathways during peak snowfall months.

StarkScapes, LLC remains committed to supporting the Canton community through dependable, high-quality exterior care across all seasons.

Media Contact
Company Name: StarkScapes, LLC
Contact Person: Kevin Collins
Email: Send Email
Phone: (330) 265-6058
Address:509 E Broad St
City: Louisville
State: OH
Country: United States
Website: https://starkscapes.com

UK Digital Health Market to Reach USD 36.84 Billion by 2030, Fueled by Tele‑Healthcare Surge and NHS Digital Upgrade

“UK Digital Health Market”
Mordor Intelligence has published a new report on the UK Digital Health Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

Mordor Intelligence, in its latest “United Kingdom Digital Health Market” report, forecasts the market will grow from USD 15.46 billion in 2025 to approximately USD 36.84 billion by 2030, at an 18.96% CAGR.The market’s fast pace underscores a broader transformation: digital tools are increasingly central to care delivery, and the national initiative to shift the NHS from legacy systems to digitised platforms represents a key shift in healthcare provision.

Report Overview: https://www.mordorintelligence.com/industry-reports/united-kingdom-digital-health-market?utm_source=abnewswire

Key Trends

1. Tele‑Healthcare Leads the Way Tele‑healthcare remains the top-grossing technology segment in 2024 and is expected to maintain rapid growth through 2030 . Its expansion is driven by patient demand for virtual consultations and providers’ desire to maintain access while easing pressure on physical clinics.

2. NHS Digitization Drive The UK government plans to invest around £21 billion (~USD 26 billion) through 2030 to digitalise NHS and social care systems from electronic patient records and cybersecurity to infrastructure like hospital Wi‑Fi and cloud environments. This commitment signals long-term market support for software, hardware, and ongoing support services.

3. Chronic Disease Management & Remote Monitoring With growing rates of chronic conditions, remote-monitoring devices and platforms that support long-term management are gaining traction. Wearables, home monitoring systems, and analytics tools are increasingly used to track patient health and reduce hospital admissions.

Market Segmentation

By Technology

  • Tele‑healthcare Remote patient consultations, virtual wards, and connected monitoring devices. For example, virtual ward usage led tele‑healthcare with a 34.6% market share in 2024

  • mHealth (mobile health) Smartphone‑based apps and services (e.g. NHS App, chronic care, wellness tools).

  • Digital Health Systems Digitized platforms such as Electronic Patient Records (EPR), hospital IT suites, and integrated clinical systems.

  • Healthcare Analytics Data-driven analytics, AI, predictive modeling fastest-growing segment with a 16.2% CAGR.

By Component

  • Software Core products including EPRs, portals, and clinical-decision platforms accounted for 58.2% of market value in 2024.

  • Hardware Devices for monitoring, IoT sensors, networking equipment.

  • Services Implementation, consulting, training, managed services growing fastest at a 13.4% CAGR.

By Application

  • Chronic Disease Management Leading application area with 41.7% share in 2024

  • Preventive & Wellness Includes fitness, lifestyle, and early-intervention digital tools.

  • Diagnostics & Decision Support AI imaging, clinical chatbots, triage systems experiencing 15.1% CAGR

  • Administration & Workflow Workflow tools, digital scribes, referral systems.

By End‑User

  • Hospitals & NHS Trusts Major buyers focused on EPRs, advanced analytics, command dashboards.

  • Primary Care & GP Practices Use NHS App, shared records, teleconsultations.

  • Patients / Home-Care Settings Remote monitoring, virtual wards, self-care apps.

  • Payers & Commissioners Integrated Care Systems (ICS) and commissioners investing in population- and outcomes-based digital solutions.

 

Key Players

The sector has a mix of established suppliers and emerging digital-health firms:

EMIS Health (Optum) – Dominant provider of electronic patient record systems across UK GP practices

PP (SystmOne) – Major EHR provider for primary and community care in the UK

Cerner Corporation – Supplies EHR systems and healthcare IT infrastructure; part of Oracle Health in the UK

Epic Systems – Leading international EHR provider with growing UK footprint.

Alcidion – UK‑based healthcare software specialist

 

Conclusion

The UK digital health market is entering a phase of strong expansion, shaped by surge in tele‑healthcare usage and strategic public investment in health technology. The NHS’s planned £21 billion infrastructure overhaul will significantly boost demand for clinical software, system integrators, cybersecurity services, and cloud operations.

Companies with scalable platforms for virtual consultations, chronic care monitoring, and integrated records stand to benefit most. Meanwhile, innovative offerings from firms like The ValueCare Group demonstrate the growing appetite for AI tools designed for proactive care. EMIS Health’s dominant position in EHR systems highlights the importance of interoperability and connectivity.

By 2030, as digital health tools weave deeper into everyday care, the UK is poised to build a more accessible, efficient, and patient-centric system. Yet to realize this potential, stakeholders will need to balance capital investment in technology with practical training and workflow integration—a task underscored by the Health Foundation’s call for sustained implementation support alongside funding

 

Industry Related Reports

Europe Digital Health Market : The Europe Digital Health Market report segments the industry as follows: By Component (Hardware, Software, Other Components), By Technology (Tele-healthcare, Mobile Health (mHealth), Health Analytics, Digital Health Systems), By Mode of Delivery (On-premise Delivery, Cloud-based Delivery), and By Geography (Germany, United Kingdom, France, Italy, Spain, Rest of Europe). The report includes five years of historical data and provides forecasts for the next five years.

Get more insights: https://www.mordorintelligence.com/industry-reports/europe-digital-health-market?utm_source=abnewswire

 

Digital Health Market : The Report Covers the Global Digital Health Market Share & Companies and is Segmented by Component (Hardware, Software, and Services), Technology (Telehealth, mHealth, Health Analytics, and Digital Health Systems), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The Report Provides the Value (in USD) for the Above Segments.

Get more insights: https://www.mordorintelligence.com/industry-reports/digital-health-market?utm_source=abnewswire

 

Europe Clinical Data Analytics Market : The Europe Clinical Data Analytics in Healthcare Market is segmented by Deployment (On-Premise, Cloud), by Application (Patient Engagement, Clinical Decision Support, Personalized Medicine, Early Disease Detection, Others), by End User (Payers, Providers), and by Country (United Kingdom, France, Germany, Italy, Spain, Rest of Europe). Includes five years of historical data and five-year market forecasts.

Get more insights: https://www.mordorintelligence.com/industry-reports/europe-clinical-data-analytics-in-healthcare-industry?utm_source=abnewswire

 

About Mordor Intelligence

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact: media@mordorintelligence.com

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: UK Digital Health Market to Reach USD 36.84 Billion by 2030, Fueled by Tele‑Healthcare Surge and NHS Digital Upgrade

Concrete Sealers Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

The Concrete Sealers Market is witnessing steady growth, driven by rising construction activities, infrastructure upgrades, and demand for long-lasting, weather-resistant surfaces. Increasing adoption in residential, commercial, and industrial sectors is boosting market expansion. Key players like BASF SE, Sika AG, PPG Industries, Arkema, and RPM International are focusing on innovation and sustainability to gain a competitive edge and meet evolving industry needs.

The concrete sealers market is estimated to be valued at USD 2.03 billion in 2024 and reach USD 2.95 billion by 2030, at a CAGR of 6.4% between 2024 and 2030. The market research study includes information on market factors such as the market dynamics, drivers, restraints, challenges, threats, concrete sealers market growth opportunities, market trends, development patterns, financial information, latest technologies, innovations, leading competitors, and regional analysis of the market. Concrete sealers are currently in high demand due to the advancements in sealer technology. Recent improvements in concrete sealer technology, including nanotechnology and eco-friendly formulations, are driving the market growth. Sealers with a nanotech base penetrate deeper into the concrete’s pores, creating a substantial barrier to moisture, chemicals, and abrasion. UV-resistant additives guard against discoloration, deterioration, and fading from the sun, providing lasting durability. In modern sealers, increased breathability enables moisture trapped within the coating to escape and reduces the coating system’s blistering and peeling, which is excellent for indoor or outdoor applications. The latest eco-friendly sealers include bio-based and low-VOC sealers, which help meet sustainability commitments and environmental protection without compromising performance.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42800526

Solvent-based sealers to be second-largest type segment in concrete sealers market, in terms of value, during forecast period

The solvent-based sealers segment is estimated to be the second-largest type in the concrete sealers market in terms of value during the forecast period. Solvent-based concrete sealers perform well in extreme conditions and provide maximum protection for heavy traffic areas, chemical protection, and wearing protection. These sealers form a hard and impenetrable barrier ideal for industrial, garage, and warehouse floors, where durability is crucial. The durability of a solvent-based sealer reduces maintenance, increases lifespan, and offers protection for concrete surfaces, making solvent sealers a popular choice for maximum protection in commercial and industrial applications.

Penetrating sealersto be fastest-growing segment, in terms of value, in concrete sealers market during forecast period

Penetrating sealers is projected to be the fastest-growing segment in the concrete sealers market during the forecast period. Penetrating sealers penetrate the concrete pores to create an internal protection layer instead of remaining on the surface. The penetrating ability offers extra durability against water, oils, and chemicals while allowing breathability. Their long-lasting performance seals the surface, which reduces the need for constant reapplication and provides an economical solution for residential and commercial use when minimal maintenance is required.

Residential to be second-largest application segment of concrete sealers market, in terms of value, during forecast period

The residential segment is estimated to be the second-largest application in the concrete sealers market in terms of value during the forecast period. Concrete surfaces around homes are subject to rain and snow, UV light, and freeze-thaw cycles, which can lead to cracking, spalling, and discoloration of the concrete. Sealers create a protective barrier that helps avoid water infiltration, limit surface degradation, and resist weather-related wear. Homeowners in severe climates prefer sealers for protecting driveways and foundations for prolonged durability and expensive repairs.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=42800526

South America to register second-highest CAGR in concrete sealers market, in terms of value, during forecast period

South America is projected to register the second-highest CAGR in the concrete sealers market in terms of value during the forecast period. With growing urbanization across countries in South America, infrastructure development is boosting the construction industry. Governments are investing in infrastructure development to support the growing population in cities, providing opportunities for protective coatings to prolong the life of concrete structures. Sealers prevent excessive wear and early breakdown due to heavy use and environmental factors, making them suitable for new construction and public works.

Concrete Sealers Companies

Key players profiled in this report include Sika AG (Switzerland), RPM International Inc. (US), Arkema (France), Mapei S.P.A. (Italy), PPG Industries Inc. (US), Prosoco (US), BASF SE (Germany), Wacker Chemie AG (Germany), Sherwin-Williams Company (US), and Evonik Industries AG (Germany).

Sika AG is a chemical company that specializes in developing and producing products for bonding, sealing, damping, reinforcing, and protecting in the construction and automotive industries. It operates through the Construction Industry and Industrial Manufacturing business segments. The company offers a range of one- and two-component plastic adhesives & sealants for various applications. Its concrete sealers are primarily offered through the Construction Industry segment. Sika AG has a significant global presence with subsidiaries in over 102 countries and manufacturing facilities in more than 400 locations worldwide. It has a strong customer base and business operations in Europe, North America, Asia Pacific, South America, Africa, and the Middle East.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=42800526

RPM International Inc. is a leading manufacturer of high-performance specialty coatings, sealants, and building materials. Its Construction Products segment generates significant revenue from concrete sealers sold under the Tremco, Euclid Chemicals, and Stonhard brands. Tremco brand specializes in performance-based sealants for concrete and coatings, while Euclid and Stonhard provide diverse repairs and flooring solutions that include sealers to help establish RPM’s position in the concrete sealers market through its Construction Products segment. RPM has 4 operating groups in some 170 countries and territories worldwide and approximately 119 manufacturing facilities in 26 countries that play a significant role in the global market.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/concrete-sealers-market-42800526.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Concrete Sealers Market 2025: Business Strategies for Excellent Growth, Highest Revenue, Booming Growth Opportunities – 2030

Electronic Filtration Market : Industry Size, Trends, Growth, Outlook, and Market Share Insights 2025-2030 | Expert Review

The Electronic Filtration Market is witnessing steady growth, driven by rising demand for cleanroom environments in semiconductors, electronics manufacturing, and data centers. Innovations in filter materials and energy-efficient solutions are further boosting adoption. Key players such as Parker Hannifin, Donaldson Company, Freudenberg, Camfil, and MANN+HUMMEL are focusing on advanced filtration technologies to enhance performance and meet stringent industry standards.

The electronic filtration market is projected to reach USD 7.06 billion by 2030 from USD 4.70 billion in 2025, at a CAGR of 8.5% during the forecast period. The market research study includes information on market factors such as the market dynamics, drivers, restraints, challenges, threats, electronic filtration market growth opportunities, market trends, development patterns, financial information, latest technologies, innovations, leading competitors, and regional analysis of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=239108694

The growth of the electronic filtration market is primarily driven by the escalating demand for semiconductors across various end-use industries, the increasing need for ultra-pure water in microelectronics applications, and the enhancement of cleanroom environments essential for semiconductor and microelectronics manufacturing. However, the market faces challenges, such as the high costs associated with advanced filtration technologies and the complexities of waste disposal resulting from filtration processes. Conversely, opportunities are emerging through the adoption of nanocomposite membranes and the growth of data centers alongside the rising trend of cloud computing services.

Liquid filters to be fastest-growing product type segment, in terms of value, during forecast period.

The liquid filters segment is anticipated to be the fastest-growing product category within the electronic filtration market, driven by the imperative to safeguard intricate and sensitive electronic components from liquid contaminants. As electronic devices continue to advance in sophistication and miniaturization, the demand for robust liquid filtration solutions to prevent damage and maintain peak performance has surged significantly. Furthermore, the increasing recognition of the pivotal role that liquid filters play in preserving the integrity of electronic systems further underlines their high growth trajectory within the electronic filtration sector.

Cleanroom environment application segment held largest market share, in terms of value, in 2024.

The cleanroom environment segment dominated the electronic filtration market in 2024, primarily due to its critical role in the pharmaceutical and semiconductor manufacturing sectors. The stringent cleanliness standards necessary to prevent contamination and maintain optimal operational conditions drive the demand for advanced filtration systems. As technology progresses and precision manufacturing becomes increasingly essential, the relevance of cleanroom environments grows, solidifying their status as the leading application within the electronic filtration industry.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=239108694

South America to be second fastest-growing regional market, in terms of value, during forecast period.

South America is projected to be the second fastest-growing regional market for electronic filtration, driven by several key factors, including industrial expansion, rapid urbanization, and heightened environmental awareness. As economic development progresses, the manufacturing sector is increasingly prioritizing air and water purification technologies to adhere to stricter environmental regulations and meet sustainability goals. This shift is further supported by a growing emphasis on advanced filtration solutions as businesses recognize the critical importance of reducing their ecological footprint and enhancing operational efficiency. The confluence of these trends is expected to significantly boost the demand for sophisticated electronic filtration systems throughout the region.

Electronic Filtration Companies

The scope of the report includes Pall Corporation (US), Entegris, Inc. (US), 3M (US), Cobetter Filtration (China), Parker Hannifin (US), Donaldson Company, inc. (US), Mott Corporation (US), Porvair PLC (UK), Mann+Hummel (Germany), and Critical Process Filtration, Inc. (US).

Pall Corporation (US) is one of the prominent players offering filtration solutions in the microelectronics market. Pall offers a broad portfolio of microelectronic filtration products, such as membranes, filters, and housings, for different applications. The firm has been able to expand its international presence after being acquired by Danaher Corporation. It has a strong presence in the high-growth geographies (emerging regions such as Eastern Europe, South America, the Middle East & Africa, and Asia (excluding Japan, Australia, and New Zealand)). Its diversified portfolio enables it to address various applications, such as semiconductors, electronics, aerospace, biotech, chemicals, medical, oil & gas, and water. Pall Corporation demonstrates a robust commitment to research and development, fostering collaborative partnerships with its clients to drive innovation in microfiltration. The company is strategically enhancing its global footprint through targeted acquisitions and strategic alliances. A significant component of its growth strategy is centered on aggressive acquisition tactics. Notably, it is in the process of establishing a new manufacturing facility in Singapore, backed by an investment of USD 100 million. This initiative is particularly advantageous for the semiconductor industry in the Asia Pacific region, especially amid the current global chip shortage, and positions Pall to scale its manufacturing capacity.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=239108694

Entegris (US) provides different filtration products for various applications in the semiconductors, data storage, flat panel displays, and solar industries. The company positions itself as a leader in science-based solutions, emphasizing innovation with a substantial investment of USD 229.0 million in R&D during 2022. This strategic focus has enabled the development of advanced technological solutions, evidenced by a remarkable 43% growth in sales from 2021 to 2022, showcasing robust market performance and financial resilience. Entegris prioritizes exceptional technical support, collaborating closely with clients to assess their requirements and deliver customized solutions.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/electronic-filtration-market-239108694.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Electronic Filtration Market : Industry Size, Trends, Growth, Outlook, and Market Share Insights 2025-2030 | Expert Review

Hindered Amine Light Stabilizers (HALS) Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2030

The Hindered Amine Light Stabilizers (HALS) market is witnessing steady growth, driven by increasing demand for UV-resistant plastics in automotive, packaging, and construction sectors. Rising awareness about material durability and environmental resistance further fuels adoption. Key players such as BASF SE, Clariant AG, ADEKA Corporation, and Solvay S.A. are actively investing in innovation and global expansion to strengthen their market presence.

The HALS market is projected to grow from USD 1.54 billion in 2024 to USD 2.32 billion by 2030, at a CAGR of 7.01%, in terms of value. The Market research study includes information on market factors such as the market dynamics, drivers, restraints, challenges, threats, HALS market growth opportunities, market trends, development patterns, financial information, latest technologies, innovations, leading competitors, and regional analysis of the market. HALS are in high demand as they protect polymers from degradation caused by UV radiation. They extend the lifespan of plastics, coatings, and fibers by neutralizing free radicals from photo-oxidation. Essential in automotive, construction, agriculture, and packaging, they improve color stability, mechanical strength, and surface appearance, promoting broader adoption. In the automotive industry, HALS are applied extensively in exterior components, paints, and dashboards to stop fading and preserve surface integrity.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265890219

In contrast, they increase the durability of siding, roofing, and sunlight-exposed pipes in buildings and construction. In the agriculture industry, HALS are incorporated in greenhouse films, mulch films, and irrigation systems to provide long-term functionality in the external environment. HALS are also used in the packaging industry to preserve plastic containers and plastic films from deterioration by UV light, maintaining product integrity and shelf life.

Building & construction is projected to be the second-largest end-use industry, in terms of value, during the forecast period.

Building and construction is projected to be the second-largest end-use industry in the global HALS market in terms of value. This is mainly led by the rising demand for durable and weather-resistant materials. HALS play a critical role in improving the lifespan and performance of construction materials such as roofing panels, siding, pipes, and outdoor paints and coatings by shielding them from UV degradation and environmental wear. As global infrastructure development continues to expand, particularly in regions with harsh weather conditions, there is an increasing demand for materials that ensure structural integrity and esthetic appeal. Additionally, stringent regulations regarding material durability and sustainability promote adopting HALS in the building and construction sector.

The polymeric HALS segment will be the fastest-growing segment in terms of value during the forecast period

The polymeric HALS segment will be the fastest-growing segment of the global HALS market during the forecast period. The major key driver of this growth is the high performance of polymeric HALS in long-term UV protection and thermal stability. The higher molecular weight of these HALS reduces volatility and restricts migration within polymer systems, ensuring consistent protection over extended periods, making them effective in applications that require enhanced durability and resistance to harsh environmental conditions. In addition, enhanced compatibility with a range of polymer types increases the formulation versatility, contributing to their increasing adoption in performance-based markets.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=265890219

North America is projected to register the second-highest CAGR, in terms of value, during the forecast period.

North America is projected to register the second-highest CAGR during the forecast period in the global HALS market, mainly driven by the rising demand for high-performance materials across key industries. The surge in automotive production, increasing investment in infrastructure projects, and growing focus on sustainable materials further contribute to the growing adoption of HALS. The stringent environmental regulations of the region are prompting the producers to incorporate advanced HALS to enhance product longevity and compliance standards. The presence of established polymer manufacturers and the ongoing advancements in material science drive the HALS market in North America.

Hindered Amine Light Stabilizers (HALS) Companies

The key players profiled in the report include BASF SE (Germany), Rianlon Corporation (China), Arkema (France), SABO S.p.A. (Italy), Syensqo SA/NV (Belgium), ADEKA Corporation (Japan), Suqian UniteChem Co., Ltd. (China), Songwon Industrial Co., Ltd. (South Korea), Clariant AG (Switzerland), and Everlight Chemical Industrial Corporation (Taiwan).

BASF SE is a key player in the HALS market with a wide range of product offerings. It operates through seven business segments: surface technologies, materials, chemicals, agricultural solutions, industrial solutions, nutrition and care, and others. It primarily supplies premium, high-performance UV stabilization solutions, and HALS through its industrial solutions business segment. In July 2024, the company launched a new product, Tinuvin NOR 211 AR. This is a new heat and light stabilizer for agricultural plastics that enhances the durability and longevity of materials exposed to UV radiation, thermal stress, and harsh chemicals, such as sulfur and chlorine. This product development strategy helps to cater to specific market demands and to maintain a competitive position in the global market. The company operates 239 production sites and has a presence in 91 countries across Europe, North America, Asia Pacific, the Middle East & Africa, and South America.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=265890219

Rianlon Corporation manufactures and supplies cost-effective UV stabilizers and anti-aging additives for polymer materials. It offers a strong product portfolio, including antioxidants, light stabilizers & HALS, and a U-pack. Its HALS solutions are a key product among its other offerings that enhance polymer materials’ durability and weather resistance. The company operates six production facilities and maintains subsidiaries in Germany, the US, Hong Kong, and Japan, along with sales offices and an extensive distributor network at a global level. It has strategically located warehouses in Europe, North America, and Asia Pacific to ensure efficient supply chain management and localized customer support. Rianlon Corporation offers localized support and technical services to maintain strong relationships with established players in key markets such as the US, Europe, and Japan. To support its long-term development plan, Rianlon Corporation acquired Hengshui Kaiya Chemical Co., Ltd. in 2019 to enhance its competency in producing HALS and expand its leadership position in polymer material anti-aging solutions.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/hindered-amine-light-stabilizers-market-265890219.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hindered Amine Light Stabilizers (HALS) Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, Scope, Demand and Forecast to 2030